MRNA close to buyI think 20$ is a good support to buy MRNA. It gave 100% of the covid gains back.
Base - Rally - Base pattern
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.965 EUR
−3.44 B EUR
3.13 B EUR
341.66 M
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
FIGI
BBG01C4Y0B99
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MR
Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine'It's gone 5 years or so... (Duh..? 5 years, really? 🥴) since everyone was talking about COVID-19 pandemic, vaccines, "world will never be the same again", and so on.
- And now?..
- It's gone. It's absolutely gone..! Since nothing last forever and no one should chase a feather, or dust in the wind.
$MRNA: Moderna – mRNA Magic or Biotech Bubble?(1/9)
Good afternoon, folks! ☀️ NASDAQ:MRNA : Moderna – mRNA Magic or Biotech Bubble?
CEO drops $5M on shares, sparking a 9% surge—is this a biotech rocket or a hot air balloon ready to pop? Let’s crack the code! 🔍
(2/9) – PRICE PERFORMANCE 📊
• Current Trend: Up 9% after CEO’s $5M buy on Mar 5,
MRNA'Ticker: MRNA
Direction: Up
Prognosis: Buy Calls (Author bought $40 and $41 calls expiring this week, considering rolling to later dates)
Reasoning: New Covid-like virus discovered, rising avian flu concerns, large institutional buying, bullish technical indicators (RSI divergence, MACD turning u
MRNA SL-$30,95 TP-$33Technical Analysis:
Weakness in bearish candles
Increase in volume may indicate a reversal
Engulfing candle on the daily chart
A reversal towards the mean on the H4 chart is likely
MACD on H4 indicates a probable inflection point
Strength on MRNADespite negative news, Moderna, Inc. stock is in a good position to rally. Its price has been falling since August 2021, but relatively big buys have begun to emerge since August 2024.
It has to be noted that on every bar with buying, volume is increasing, which is usually a sign of accumulation on
Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment a
MRNA Moderna Options Ahead of EarningsIf you haven`t bought MRNA before the previous earnings:
Now analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 45usd strike price Calls with
an expiration date of 2025-9-19,
for a premium of approximately $3.
$MRNA yieahhhrough day for some, good day for my DCA friends.
NASDAQ:MRNA on a rough down trend since covid days. Looking for a wild bounce here.
1. MACD curving to the upside
2. RSI Curving to the upside
3. Price is at the bottom of the parallel channel.
My bets are on seeing $60-$70 which is middle of th
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 1MRNA is featured.
Related stocks
Frequently Asked Questions
The current price of 1MRNA is 21.820 EUR — it has increased by 1.34% in the past 24 hours. Watch MODERNA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange MODERNA stocks are traded under the ticker 1MRNA.
1MRNA stock has fallen by −6.00% compared to the previous week, the month change is a −26.29% fall, over the last year MODERNA has showed a −77.27% decrease.
We've gathered analysts' opinions on MODERNA future price: according to them, 1MRNA price has a max estimate of 186.50 EUR and a min estimate of 17.59 EUR. Watch 1MRNA chart and read a more detailed MODERNA stock forecast: see what analysts think of MODERNA and suggest that you do with its stocks.
1MRNA reached its all-time high on Dec 14, 2022 with the price of 203.000 EUR, and its all-time low was 20.670 EUR and was reached on Apr 7, 2025. View more price dynamics on 1MRNA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1MRNA stock is 1.68% volatile and has beta coefficient of 0.99. Track MODERNA stock price on the chart and check out the list of the most volatile stocks — is MODERNA there?
Today MODERNA has the market capitalization of 8.42 B, it has decreased by −4.49% over the last week.
Yes, you can track MODERNA financials in yearly and quarterly reports right on TradingView.
MODERNA is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
1MRNA earnings for the last quarter are −2.81 EUR per share, whereas the estimation was −2.59 EUR resulting in a −8.57% surprise. The estimated earnings for the next quarter are −2.88 EUR per share. See more details about MODERNA earnings.
MODERNA revenue for the last quarter amounts to 933.13 M EUR, despite the estimated figure of 910.74 M EUR. In the next quarter, revenue is expected to reach 109.44 M EUR.
1MRNA net income for the last quarter is −1.08 B EUR, while the quarter before that showed 11.68 M EUR of net income which accounts for −9.37 K% change. Track more MODERNA financial stats to get the full picture.
No, 1MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 5.8 K employees. See our rating of the largest employees — is MODERNA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MODERNA EBITDA is −3.63 B EUR, and current EBITDA margin is −116.07%. See more stats in MODERNA financial statements.
Like other stocks, 1MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MODERNA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MODERNA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MODERNA stock shows the sell signal. See more of MODERNA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.